EXTON, Pa., March 16, 2021 – AGC Chemicals now offers small-molecule active pharmaceutical ingredient (API) contract manufacturing services. With comprehensive technical expertise and current good manufacturing practice (cGMP) facilities around the world, AGC is uniquely positioned to provide custom synthesis for clinical trials, process R&D and commercial scale-up of these fine chemicals for pharmaceutical products.
AGC’s contract manufacturing services help pharmaceutical companies accelerate product development and reduce costs through efficient and proven processes. With cGMP plants in Chiba, Japan, and Barcelona, Spain, AGC is a reliable global supply chain partner. AGC can provide multistep synthesis of key intermediates, raw materials and APIs at yearly quantities from 100 kilograms to 100 metric tons.
AGC’s core technologies include direct or indirect fluorination, specializing in hazardous chemistry including:
For more information about AGC’s products and services for the pharmaceutical industry, visit the specialty intermediates and fine chemicals page at AGC’s global site: https://www.agc-chemicals.com/gb/en/company/chemical_chain/lifescience/index.html
AGC Chemicals Americas is a wholly owned subsidiary of AGC Inc., a $14.1 billion multinational corporation and one of the world’s largest manufacturers of glass, electronic displays and chemical products. The company was formed in 2004 through the merging of sister companies Asahi Glass Fluoropolymers USA and AGA Chemicals. Headquartered in Exton, Pennsylvania, including a state-of-the-art technology center, AGC Chemicals Americas maintains manufacturing operations in nearby Thorndale, Pennsylvania, a satellite sales office in Sao Paulo, Brazil and warehouses located throughout North America. www.agcchem.com